STEGLATRO (ertugliflozin) tablets

STEGLATRO is a brand-name prescription drug that’s FDA-approved to treat type 2 diabetes . Brand Name: STEGLATRO (ertugliflozin) tablets, for oral use Initial U.S. Approval: 2017

STEGLATRO (ertugliflozin) tablets Price In India and Overseas
STEGLATRO (ertugliflozin) tablets

Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!

For Indian Patient Enquiry under NPP.

For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.

STEGLATRO (ertugliflozin) tablets

Steglatro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise as monotherapy when metformin is considered inappropriate due to intolerance or contraindications or in addition to other medicinal products for the treatment of diabetes.

• STEGLATRO is a prescription medicine used in adults with type 2 diabetes to improve blood sugar
(glucose) control along with diet and exercise.
• STEGLATRO is not for people with type 1 diabetes. It may increase the risk of diabetic ketoacidosis
in these people.
• It is not known if STEGLATRO is safe and effective in children under 18 years of age.

Ertugliflozin, sold under the brand name Steglatro, is a medication for the treatment of type 2 diabetes. The most common side effects include fungal infections of the vagina and other infections of the female reproductive system. Ertugliflozin is a sodium/glucose cotransporter 2 (SGLT2) inhibitor and is in the class of drugs known as gliflozins. In the United States, it was approved by the Food and Drug Administration for use as a monotherapy and as a fixed dose combination with either sitagliptin or with metformin. In the European Union, it was approved in March 2018, for use as a monotherapy or combination therapy

Drug (Brand / Generic): STEGLATRO / ertugliflozin
Current Indications: type 2 diabetes
Marketed by:: Merck Sharp & Dohme Corp.
Approval Date: 2017

Available as (Form & Strength): Tablets: 5 mg and 15 mg

For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here

Alleviare Life Sciences

About Us

Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.

Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.

Alleviare India, a certified pharmaceutical facilitator / supplier / importer of specialty medicines or drugs based in India.